Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 139 record(s)

Req # A-2020-001628

Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_02169963.

Organization: Health Canada

19 page(s)
November 2021

Req # A-2020-001633

Adverse Drug Reactions (ADRs) for INSULIN GLARGINE. Report numbers: 000914885, E2B_03177640, 000917355, E2B_03179056, E2B_03187375, E2B_03217648, E2B_03228735, E2B_03253131, E2B_03269421.

Organization: Health Canada

84 page(s)
November 2021

Req # A-2020-001643

Adverse Drug Reactions (ADRs) for METFORMIN HYDROCHLORIDE. Report numbers: 000913712, E2B_03197852, E2B_03266230, 000919396.

Organization: Health Canada

78 page(s)
November 2021

Req # A-2020-001690

Adverse Drug Reaction (ADR) for Mictoryl (propiverine hydrochloride). Report number: 000921739 ADR for Prevegyne (ascorbic acid). Report number: E2B_03314548 .

Organization: Health Canada

85 page(s)
November 2021

Req # A-2020-001752

Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03452307.

Organization: Health Canada

13 page(s)
November 2021

Req # A-2020-001939

Adverse Drug Reactions (ADRs) for Mezavant. Report numbers: E2B_03538381, E2B_03538386, E2B_03535705, E2B_03592302, E2B_03538369, E2B_03524778, E2B_03524679, E2B_03524716, E2B_03536534, E2B_03538403.

Organization: Health Canada

139 page(s)
November 2021

Req # A-2021-000022

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-101660-573.

Organization: Health Canada

8 page(s)
November 2021

Req # A-2021-000024

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-116088-925.

Organization: Health Canada

2 page(s)
November 2021

Req # A-2021-000037

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-100545-362.

Organization: Health Canada

8 page(s)
November 2021

Req # A-2021-000099

Adverse Drug Reactions (ADRs) for Varivax III. Report numbers: 000705268, 000706552, 000707195. ADRs for Zepatier. Report numbers: E2B_01496721, 000703672, 000704255, 000705883, 000706683. ADRs for Zostavax. Report numbers: E2B_01742359, E2B_01747192.

Organization: Health Canada

81 page(s)
November 2021
Date modified: